Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users

Substance Use and Misuse

Volumn 44, Issue 4, 2009, Pages 548-568

  Cox, Joseph ^a,b,c,d,f   Morissette, Carole ^a,d   De, Prithwish ^b   Tremblay, Claude ^a   Allard, Robert ^a,b,d   Graves, Lisa ^c   Stephenson, Randolph ^c   Roy, Élise ^a,b,d,e  

^a Gouvernement du Quebec   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE   (Canada)

^e UNIVERSITÉ DE SHERBROOKE   (Canada)

^f Division of Infectious Diseases   (Canada)

Author keywords

Counseling; Guidelines; Hepatitis C; Paraphernalia sharing; Receptive sharing; Risk hierarchy; Screening; Social network; Syringe exchange program (SEP)

Indexed keywords

METHADONE;

ADULT; ARTICLE; AWARENESS; CANADA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPENDENT VARIABLE; DRUG ABUSE; FEMALE; HEALTH STATUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; INTERVIEW; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEEDLE; PATIENT COUNSELING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; SOCIAL NETWORK; SYRINGE; ATTITUDE TO HEALTH; MIDDLE AGED; PREVENTIVE HEALTH SERVICE; PSYCHOLOGICAL ASPECT; SOCIAL SUPPORT; STATISTICAL MODEL; SUBSTANCE ABUSE; VIROLOGY;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPATITIS C; HUMANS; INTERVIEWS AS TOPIC; LOGISTIC MODELS; MALE; METHADONE; MIDDLE AGED; NEEDLE-EXCHANGE PROGRAMS; QUEBEC; RISK-TAKING; SOCIAL SUPPORT; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 66149192688     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1080/10826080802544349     Document Type: Article

References (43)

1. Alter, M. J., Seeff, L. B., Bacon, B. R., Thomas, D. L., Rigsby, M. O., Di Bisceglie, A. M. (2004). Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Annals of Internal Medicine, 141:715-717.
2. Best, D., Noble, A., Finch, E., Gossop, M., Sidwell, C., Strang, J. (1999). Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. British Medical Journal, 319:290-291.
3. Bowden, S., McCaw, R., White, P. A., Crofts, N., Aitken, C. K. (2005). Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. Journal of Viral Hepatitis, 12:322-324.
4. Centers for Disease Control and Prevention (1998). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recommendations and Reports, 47(RR-19):1-39.
5. Cox, J., Stephenson, R., Morissette, C., Roy, E., Graves, L., Allard, R., Mereb, C. (2002). Development of a questionnaire on hepatitis C-related knowledge, attitudes and behaviors of injection drug users. Journal of Urban Health,79(4):S99.
6. Craine, N., Walker, M., Carnwath, T., Klee, H. (2004). Hepatitis C testing and injecting risk behaviour: the results of a UK based pilot study. International Journal of Drug Policy, 15:115-122.
7. Darke, S. (1998). Self-report among injecting drug users: a review. Drug and Alcohol Dependence, 51:253-263.
8. Davis, M., Rhodes, T., Martin, A. (2004). Preventing hepatitis C: "common sense", "the bug" and other perspectives from the risk narratives of people who inject drugs. Social Science and Medicine, 59:1807-1818.
9. Direction de santé publique de Montréal. (2006). VIH/Hépatite C - Information aux professionnels. Appel à la vigilance - Août 2006: Recrudescence d'infections par le virus de l'immunodéficience humaine (VIH) et le virus de l'hépatite C (VHC) chez les utilisateurs de drogues injectables (UDI) de Montréal. Retrieved January 10, 2008, from http://www.santepub-mtl.qc.ca/Mi/vigilance/ 31082006.html.
10. Dowling-Guyer, S., Johnson, M. E., Fisher, D. C., Needle, R., Waltters, J., Andersen, M., Williams, M., Kotranski, L. (1994). Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported drug use. Assessment, 1:383-392.
11. Graves, L., Cox, J., Lambert-Lanning, A., Stephenson, R., Steben, M. (2005, October). Knowledge, perceptions and attitudes of Canadian family physicians about Hepatitis C. Poster session presented at the North American Primary Care Research Group Annual Meeting, Quebec City, Canada. Retrieved January 10, 2007, from http://www.fmdrl.org/index.cfm? event=c. AccessResourceandrid=213.
12. Hagan, H., Campbell, J., Thiede, H., Strathdee, S., Ouellet, L., Kapadia, F., Hudson, S., Garfein, R. S. (2006). Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Reports, 121:710-719.
13. Hagan, H., Jarlais, D. C., Friedman, S. R., Purchase, D., Alter, M. J. (1995). Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. American Journal of Public Health, 85:1531-1537.
14. Hagan, H., Thiede, H., Weiss, N. S., Hopkins, S. G., Cuchin, J. S., Alexander, E. R. (2001). Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health, 91:42-46.
15. Hahn, J. A., Page-Shafer, K., Lum, P. J., Bourgois, P., Stein, E., Evans, J. L., Busch, M. P., Tobler, L. H., Phelps, B., Moss, A. R. (2002). Hepatitis C virus seroconversion among young injection drug users: relationships and risks. Journal of Infectious Diseases, 186:1558-1564.
16. Hankins, C., Alary, M., Parent, R., Blanchette, C., Claessens, C., the SurvUDI Working Group. (2002). Continuing HIV transmission among injection drug users in Eastern Central Canada: the SurvUDI Study, 1995 to 2000. Journal of Acquired Immune Deficiency Syndromes, 30:514-521.
17. Hartel, D. M., Schoenbaum, E. E., Selwyn, P. A., Friedland, G. H., Klein, R. S., Drucker, E. (1997). Patterns of heroin, cocaine and speedball injection among Bronx (USA) methadone maintenance patients: 1978-1988. Addiction Research, 8:394-404.
18. Health Canada and The College of Family Physicians of Canada. (2002). Physicians' desk reference: primary care management of hepatitis C. Retrieved January 10, 2007, from http://www.cfpc.ca/English/cfpc/programs/ patient%20care/hepatitis%20c/primary/default.asp?s=1.
19. Heimer, R., Clair, S., Grau, L. E., Bluthenthal, R. N., Marshall, P. A., Singer, M. (2002). Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction, 97:1277-1287.
20. Herring, B. L., Page-Shafer, K., Tobler, L. H., Delwart, E. L. (2004). Frequent hepatitis C virus superinfection in injection drug users. Journal of Infectious Diseases, 190:1396-1403.
21. Hosmer, Jr., D. W., Lemeshow, S. (1989). Applied logistic regression. New York: John Wiley.
22. Joseph, J. G., Emmons, C. A., Kessler, R. C., Wortman, C. B., O'Brien, K., Hocker, W. T., Schaefer, C. (1984). Coping with the threat of AIDS. An approach to psychosocial assessment. American Psychologist, 39:1297-1302.
23. Koester, S., Booth, R. E., Zhang, Y. (1996). The prevalence of additional injection-related HIV risk behaviors among injection drug users. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 12:202-207.
24. Kwiatkowski, C. F., Fortuin Corsi, K., Booth, R. E. (2002). The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction, 97:1289-1294.
25. Latkin, C. A., Forman, V., Knowlton, A., Sherman, S. (2003). Norms, social networks, and HIV-related risk behaviors among urban disadvantaged drug users. Social Science and Medicine, 56:465-476.
26. Leclerc, P., Morissette, C. (2006a). Situation épidé miologique des infections transmissibles sex-uellement et par le sang (ITSS) pour la région de Montréal. Pascale Leclerc, Carole Morissette. Direction de santé publique de Montréal. Retrieved January 10, 2007, from http://www.santepub-mtl.qc.ca/Publication/mts/itsssituation.html.
27. Leclerc, P., Morissette, C., Roy, É., Tremblay, C., Alary, M. (2006b, October). Accès au matériel stérile d'injection et aux soins médicaux pour les utilisateurs de drogues par injection de Montréal. Poster session presented at the Les journées annuelles de santé publique, Montreal, Quebec, Canada.
28. Loxley, W., Bolleter, A., Carruthers, S. (2001). Talking about testing: opportunities for prevention in blood borne virus testing and vaccination with injectors. Australia: National Drug Research Institute, Perth.
29. Morissette, C., Cox, J., De, P., Tremblay, C., Roy, E., Allard, R., Stephenson, R., Graves, L. (2007). Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention. International Journal of Drug Policy, 18:204-212.
30. Needle, R. H., Coyle, S., Cesari, H., Trotter, R., Clatts, M., Koester, S., Price, L., McLellan, E., Finlinson, A., Bluthenthal, R. N., Pierce, T., Johnson, J., Jones, T. S., Williams, M. (1998). HIV risk behaviors associated with the injection process: multiperson use of drug injection equipment and paraphernalia in injection drug user networks. Substance Use and Misuse, 33:2403-2423.
31. National Institutes of Health Expert Panel. (2002). NIH consensus statement on management of hepatitis C: 2002. NIH Consensus State Science Statements 19:1-46. Retrieved August 20, 2006, from http://consensus.nih. gov/2002/2002HepatitisC2002116PDF.pdf.
32. Ompad, D. C., Fuller, C. M., Vlahov, D., Thomas, D., Strathdee, S. A. (2002). Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clinical Infectious Diseases, 35:783-788.
33. Prochaska, J. O., DiClemente, C. C., Norcross, J. C. (1992). In search of how people change: applications to addictive behaviors. American Psychologist, 47:1102-1114.
34. Remis, R. S., Bruneau, J., Hankins, C. A. (1998). Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18(Suppl. 1):S57-S59.
35. Rhodes, T., Davis, M., Judd, A. (2004). Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction, 99:621-633.
36. Roy, É., Alary, M., Morissette, C., Leclerc, P., Boudreau, J-F., Parent, R., Rochefort, J., Claessens, C. and The SurvUDI Working Group. (2007). High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. International Journal of STD and AIDS, 18:23-27.
37. Shehab, T. M., Sonnad, S. S., Jeffries, M., Gunaratnum, N., Lok, A. S. (1999). Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology, 30:794-800.
38. Sherman, M., Bain, V., Villeneuve, J. P., Myers, R. P., Cooper, C., Martin, S., Lowe, C. (2004). The management of chronic viral hepatitis: A Canadian consensus conference 2004. Canadian Journal of Infectious Diseases & Medical Microbiology, 15:313-326.
39. Stein, M.D., Maksad, J., Clarke, J. (2001). Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence, 61:211-215.
40. Thorpe, L., Ouellet, L. J., Hershow, R., Bailey, S. L., Williams, I. T., Williamson, J., Monterroso, E. R., Garfein, R. S. (2002). Risk of hepatitis C virus injection among young adult injection drug users who share injection equipment. American Journal of Epidemiology, 155:645-653.
41. US Preventive Services Task Force. (2004). Screening for hepatitis C virus infection in adults: recommendation statement. Annals of Internal Medicine, 140:462-464.
42. Vid al -Trécan, G., Coste, J., Varescon-Pousson, I., Christoforov, B., Boissonnas, A. (2000). HCV status knowledge and risk behaviours amongst intravenous drug users. European Journal of Epidemiology, 16:439-445.
43. Zimmerman, G. L., Olsen, C. G., Bosworth, M. F. (2000). A "stages of change" approach to helping patients change behavior. American Family Physician, 61:1409-1416.